SH 110
Alternative Names: SH-110Latest Information Update: 10 Oct 2023
At a glance
- Originator Shorla Pharma
- Developer Shorla Oncology
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Glioblastoma
Most Recent Events
- 09 Oct 2023 Shorla Oncology plans to launch SH 110 for treatment of Glioblastoma in USA (PO) in Q2 2026 (Shorla Oncology pipeline, October 2023)
- 15 Jul 2022 Clinical trials in Glioblastoma in Ireland (PO) (Shorla Oncology pipeline, July 2022)
- 19 Feb 2021 Shorla Pharma has patent pending for SH 110 before February 2021 (Shorla Pharma pipeline, February 2021)